ArticleiScience2022
Intravenous nicotinamide riboside elevates mouse skeletal muscle NAD
Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals.JCI insight · 2022Trial
- Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.Scientific reports · 2022Trial
- Repeated Disuse Atrophy Imprints a Molecular Memory in Skeletal Muscle: Transcriptional Resilience in Young Adults and Susceptibility in Aged Muscle.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intravenous infusion of nicotinamide adenine dinucleotide (NADFrontiers in aging · 2026Article
- Long-term high-protein diet intake accelerates adipocyte senescence through macrophage CD38-mediated NADMolecular metabolism · 2026Article
- From Bench to Clinic: The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling.Molecular medicine (Cambridge, Mass.) · 2025Article
- Emerging strategies, applications and challenges of targeting NADNature aging · 2025Review
- Nicotinamide riboside and nicotinamide mononucleotide facilitate NADScience advances · 2025Article
- Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns.Endocrine reviews · 2023Review
- Nicotinamide Riboside, a Promising Vitamin BMolecules (Basel, Switzerland) · 2023Review
- NAMPT-dependent NADProceedings of the National Academy of Sciences of the United States of America · 2023Article
- NADSports medicine (Auckland, N.Z.) · 2022Review
- Circadian cardiac NADAmerican journal of physiology. Cell physiology · 2022Review
- Pterostilbene Fails to Rescue Insulin Secretion and Sensitivity in Multiple Murine Models of Diabetes.Nutrients · 2022Article
- Balancing NADCellular and molecular life sciences : CMLS · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In clinical trials, oral supplementation with nicotinamide riboside (NR) fails to increase muscle mitochondrial respiratory capacity and insulin sensitivity but also does not increase muscle NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.